Background illustration for clinical trials search

Paid Clinical Trials Houston

Discover 3,132 paid clinical trials in Houston, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 3,132

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

for

Advanced Systemic Mastocytosis (AdvSM),

Location: Houston TX, Atlanta GA, Charleston SC, Phoenix AZ,

Sponsor: Cogent Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT04996875

Phase 2, Recruiting

Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism

for

Primary Hyperparathyroidism

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 0+

Code: NCT03052075

Recruiting

Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)

for

Human Papillomavirus

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 21+

Code: NCT06434337

Recruiting

Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol

for

Advanced Cancers

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 0+

Code: NCT00851032

Recruiting

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

for

Breast Carcinoma, Invasive Breast Carcinoma

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05406232

Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

for

Recurrent Chronic Lymphocytic Leukemia,

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04169737

Phase 2, Recruiting

Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain

for

Hypophysectomy

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06287515

Phase 1, Recruiting

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

for

Glioblastoma

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06672575

Phase 1, Phase 2, Recruiting

Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

for

Solid Tumor

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06563375

Phase 1, Recruiting

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

for

Acute Myeloid Leukemia,

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 12+

Code: NCT03383575

Phase 2, Recruiting

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

for

Chronic Lymphocytic Leukemia (CLL),

Location: Houston TX, Nashville TN, Denver CO, Chicago IL,

Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT04830137

Phase 1, Recruiting

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

for

Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer,

Location: Houston TX, Dallas TX, Atlanta GA, Coral Gables FL,

Sponsor: SillaJen, Inc.

Sex: All

Age: 18+

Code: NCT05768932

Phase 1, Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

for

Non Small Cell Lung Cancer, Esophageal Cancer,

Location: Houston TX, Nashville TN, Louisville KY, Greenville SC,

Sponsor: SystImmune Inc.

Sex: All

Age: 18+

Code: NCT05983432

Phase 1, Recruiting

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

for

Advanced Malignant Solid Neoplasm,

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05039632

Phase 1, Phase 2, Recruiting

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

for

Solid Tumor

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06576037

Phase 1, Recruiting

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

for

Recurrent Acute Myeloid Leukemia,

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04140487

Phase 1, Phase 2, Recruiting

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

for

Breast Cancer

Location: Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT05042687

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

for

Advanced Unresectable Solid Tumor, Metastatic Solid Tumor

Location: Houston TX, Dallas TX, Birmingham AL, Saint Louis MO,

Sponsor: TopAlliance Biosciences

Sex: All

Age: 18+

Code: NCT04137900

Phase 1, Recruiting

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

for

Inflammatory Breast Carcinoma, Invasive Breast Carcinoma,

Location: Houston TX, Sugar Land TX, Nassau Bay TX,

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT00477100

Recruiting

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

for

Carcinoma, Non-Small-Cell Lung

Location: Houston TX, Sioux Falls SD, Columbus OH, Fargo ND,

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT04165070

Phase 1, Phase 2, Recruiting

Want a closer look at research in Houston? Read our guide: Clinical Trials in Houston: Why the City Leads the Country

Houston Has More Recruiting Clinical Trials Than Any US City

Paid Clinical Trials Houston

Filter results

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism

Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)

Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Interested in new trials?

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)